Tag Archives: Jim Greenwood

BIO Member Company Achieves Significant Milestone in Advanced Biofuel Technology

abengoa-fermentation-tank-115x76

On Friday, October 17, 2014, Abengoa Bioenergy opened its 25-million gallon per year cellulosic ethanol biorefinery in Hugoton, Kansas.  Abengoa completed the construction of its facility in mid-August and began producing cellulosic ethanol at the end of September. The plant produces up to 25 million gallons a year using only raw biomass “second generation” for the production of ethanol, ie residues of agricultural crops and inedible stems and leaves that do not compete with grain for feed materials. Through Read More >

Biofuels & Climate Change  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Ebola Highlights Importance of Vaccine Development in Protecting Global Health

21st-Century-Cures--Free

The current Ebola crisis shows how government regulators and research institutions, global health organizations, and biopharmaceutical research companies can work collaboratively and efficiently to speed the development of novel vaccines and therapeutics in response to an urgent global health problem. Yet just as importantly, it underscores the need to move innovation forward before a crisis breaks out in order to prevent illness and suffering, and save the lives of countless people around the world. Vaccines Read More >

Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Cancer drugs save and extend lives

medical_research

This week, CBS aired a misleading segment on the cost of innovative cancer therapies. BIO immediately responded by pointing out that the segment completely ignored the value created by these drugs for patients and the healthcare system. “Cancer patients today are able to live longer and enjoy a higher quality of life than ever before thanks to medicines made by biopharmaceutical research companies,” said Jim Greenwood, BIO President and CEO. “Advances in cancer treatment are Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

San Francisco Chronicle: High Drug Co-Pays Deny Needed Treatments

Jim Greenwood

Today, the San Francisco Chronicle published an op-ed that I wrote on the importance of ensuring access to treatments for debilitating diseases that are saving millions of patients from pain and possible death. Patients rightly expect their health insurance plan to cover the best medicines based on their unique needs, at an out-of-pocket cost that makes these therapies accessible. Insurance companies and their allies, seeking to deflect blame for increased premiums at a time of Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Jim Greenwood in WSJ: Curing Hepatitis C Is Cheaper Than Open-Ended Care

Jim Greenwood

On Friday, a letter from BIO President and CEO Jim Greenwood was published in the Wall Street Journal, arguing that curing hepatitis C is cheaper than the alternative of open ended care. The full text of the letter is below: President and CEO of America’s Health Insurance Plans (HIP) Karen Ignagni’s “Paying for the Thousand-Dollar Pill” (op-ed, Aug. 4) plays down the fact that Sovaldi has been shown to achieve a high cure rate for Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , ,